Versantis is a pharmaceutical company specialized in the development of Versantis is a spin-off company from ETH Zürich. The company develops transformative orphan drugs in liver and pediatric diseases with the goal to revolutionize the critical care of cirrhosis decompensations and neonatal hyperammonemic crises. The lead candidate, VS-01, is a proprietary first-line treatment in clinical-stage for acute liver diseases able to simultaneously support the failing liver, brain, and kidney.
- CEO & co-Founder: Vincent Forster
- COO & co-Founder: Meriam Kabbaj
- Location: Zurich
- Website: versantis.ch
- Acquisition: Genfit